Lonza’s Post

In our Q1 Qualitative Update, we reported performance in line with expectations for Full-Year 2024. A softer performance in the first quarter is expected to normalize across H1 2024.   “We made good progress in Q1 2024 with the strategic acquisition of the large-scale biologics site in Vacaville and the appointment of Lonza’s new CEO, Wolfgang Wienand," said Albert Baehny, CEO ad interim. "Looking at our industry fundamentals, we remain well-positioned to capture value by maintaining our focus on growing our commercial offering, while managing our costs and maintaining our focus on operational excellence.”   Read more here: https://lnkd.in/gRMQpNFx   #AHealthierWorld #AMeaningfulDifference #PharmaceuticalManufacturing

Today, we welcome Jean-Marc Huët as our new Chairman of the Board, following his election by shareholders at our Annual General Meeting. Jean-Marc has a strong international leadership track record and extensive operational and strategic management experience in the consumer, pharma and nutrition industries. As we congratulate Jean-Marc on his appointment, we also extend our thanks to Albert Baehny for his leadership during his six years as Chairman of Lonza. Albert will retire from Lonza this summer after handing over to incoming CEO Wolfgang Wienand.

Join us for two fascinating presentations at BioTalk US this week! Penny Douglas, Principal Scientist 📅 Wednesday, 8 May 🕣 9:30am 'Innovative analytical strategies for new molecular format CMC development, focusing on BLA' Anasuya Dilaver, Associate Principal Scientist 📅 Wednesday, 8 May 🕣 3:20pm 'Accelerating the development of new molecular formats: speed to clinic' We hope to see you there!

If you're at PEGS Boston, make sure to catch Devarshi Kapadia's presentation: "Solutions for High Titre Expression of Cancer Immunotherapies" 📅 Monday, 13 May, 2024 🕣 12:35 pm 📍 Antibodies for Cancer stream #LonzaExpressionSystems #LonzaInYourLab #viralVectors #exosomes #geneTherapy #biotechnology

Connie joined Lonza in 2021 and works as a Material Planner at our site in Stein, Switzerland. "I am very proud of working at Lonza, where it helped me grow both professionally and personally, and as I often say to my coworkers: I come to work not because 'I have to' but because 'I want to'. I am passionate about what I do and what the company does. What I appreciate the most is the work environment. Lonza supports and encourages each employee’s opinion. I work with talented people every day, where I make a meaningful difference." Read Connie's full story here: https://lnkd.in/dV6-J4j2 #AMeaningfulDifference #CareerGrowth #Opportunities #PharmaceuticalManufacturing

Join Lonza's #mRNA experts next week, as they explore how to simplify nucleic acid encapsulation with new available technologies. 📅 Monday, 6 May 🕝 11am EDT / 5pm CET Register here: https://lnkd.in/e2HjDe5e #Lonza #Biologics #Technology

Welcome to ‘Biologics In Focus’, the new newsletter from Lonza Biologics. Each month we will deliver deep analysis of industry trends, expert insights, and an overview of upcoming events - as well as the latest Lonza news and real world customer stories. In this month’s highlights: ◾ read our survey findings on next-gen therapeutics development hurdles ◾ discover our best practices for biologics tech transfers ◾ hear from Asher Biotherapeutics about their own tech transfer success   Subscribe now to make sure you receive the next edition of Biologics In Focus #LonzaBio #pharma #biotechnology #thePeoplePoweringBiologics

How is Lonza using Machine Learning and Artificial Intelligence? Lonza experts Simon Wagschal and Aaron Johnson discuss AI, Machine Learning and Industry 4.0 with European Pharmaceutical Manufacturer. "One area where AI is being leveraged is the manufacturing of Active Pharmaceutical Ingredients (APIs). APIs are continuing to grow more complex, impacting speed-to-clinic. These longer synthetic pathways present challenges for process chemists hoping to achieve an efficient API manufacturing process," said Aaron Johnson, Manager of Cheminformatics & Data Science at Lonza. "Machine Learning is used in synthetic process route design, process optimization, toxicological assessment of new chemical entities, and formulation design. In one aspect of IND-enabling work, process chemistry subject matter experts devise prospective synthetic pathways from commercially accessible starting materials to arrive at a target API," said Simon Wagschal, Associate Director of Advanced Chemistry Technologies at Lonza. Read the full Q&A on page 20 of European Pharmaceutical Manufacturer's March/April edition: https://lnkd.in/d7MmjQKK #AHealthierWorld #PharmaceuticalManufacturing #AI #MachineLearning

We have just launched our AI-enabled Route Scouting Service, which aims to streamline synthetic route identification for novel APIs by combining our global chemical supply chain intelligence and in-house expertise with AI technology from Elsevier (Reaxys). The complexity of small molecule APIs entering the development pipeline is steadily increasing, and the intricate structures of modern drug candidates are driving an increase in the number of synthetic steps required to produce them. With access to global chemical supply chain intel and the predictive power of award-winning AI, the new offering provides synthetic pathways that are more supply chain resilient and offer insights for optimal route design on both clinical and commercial manufacturing. The integrated service can provide intellectual property, reduce COGS and improve supply chain security for customers. Read more: https://lnkd.in/dTi42TD2 #AHealthierWorld #SmallMolecules #PharmaceuticalManufacturing #ArtificialIntelligence #Innovation